-
Mashup Score: 4
A collaborative effort between CMML researchers and The Leukemia & Lymphoma Society hopes to jump-start CMML research.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Douglas Tremblay, MD, on Venetoclax Plus HMA in Patients With CMML | Blood Cancers Today - 26 day(s) ago
The study also explored the role of this combination in transitioning patients with CMML to HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
A collaborative effort between CMML researchers and The Leukemia & Lymphoma Society hopes to jump-start CMML research.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
A collaborative effort between CMML researchers and The Leukemia & Lymphoma Society hopes to jump-start CMML research.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
The Leukemia and Lymphoma Society’s CMML initiative hopes for dedicated CMML trials and CMML-directed therapies.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Douglas Tremblay, MD, on Venetoclax Plus HMA in Patients With CMML | Blood Cancers Today - 1 month(s) ago
The study also explored the role of this combination in transitioning patients with CMML to HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 140Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management - 2 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Chronic myelomonocytic leukemia - 4 month(s) ago
Clonal myeloid neoplasm defined by persistent relative (> 10%) and absolute monocytosis (≥1 x 109/L) in peripheral blood Features of both a myeloproliferative neoplasm and a myelodysplastic syndrome
Source: www.pathologyoutlines.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Triplet Combination Yields Encouraging Activity for Newly Diagnosed Secondary AML, MDS, or CMML After Failure of Hypomethylating Agents - 7 month(s) ago
The combination of azacitidine, venetoclax, and pevonedistat yielded encouraging efficacy among a poor-risk population of patients with AML, MDS or CMML, according to a phase 1/2 trial.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? | ASH Clinical News | American Society of Hematology - 10 month(s) ago
Ioannis Kotsianidis, MD Mrinal M. Patnaik, MBBS The U.S. Food and Drug Administration has approved two hypomethylating agents (HMAs), azacitidine and decitabine, for the treatment of chronic myelomonocytic leukemia (CMML), a rare and aggressive myeloid malignancy with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).1,2 Despite being widely…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
#CMML has lingered in the penumbra of MDS, but a collaborative effort hopes to jump-start understanding of this rare disease. Check out our latest feature, with insight from Lee Greenberger, PhD, of @LLSusa; @md_padron of @MoffittNews; and more! 📖 https://t.co/kBO2K3jGB8 https://t.co/qMROsHshov